High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Significance: Nanoparticle-mediated delivery of siRNA to hepatocytes has treated disease in humans. However, systemically delivering RNA drugs to nonliver tissues remains an important challenge. To increase the number of nanoparticles that could be studied in vivo, we designed a high-throughput method to measure how >100 nanoparticles delivered mRNA that was translated into functional protein in vivo. We quantified how >250 lipid nanoparticles (LNPs) delivered mRNA in vivo, identifying two LNPs that deliver mRNA to endothelial cells. One of the LNPs codelivered Cas9 mRNA and single-guide RNA in vivo, leading to endothelial cell gene editing. This approach can identify nanoparticles that target new cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Such assemblies, complexed with polymers capable of disrupting endosomes and including DNA templates for homology-directed repair, were found to promote correction of dystrophin gene mutations in mice 80 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. A., Gu, H., Ng, L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2467 · Cited by 6,907
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390 · cited 1×
“To confirm protein silencing was mediated by gene editing, we measured (40) ICAM-2 insertions and deletions (indels) in lung, spleen, and kidney endothelial cells and found between 30 and 70% editing per locus, leading to overall ICAM-2 indel percentages of 135, 95, and 123% indel, respectively for 7C2 (Fig.”
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Self-citationRational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“Moreover, LNP siRNA delivery is often tested in vivo using the FVII assay, which predicts hepatocyte delivery; this assay is enhanced by its ease, as well as the fact that validated, potent siRNA targeting FVII is available (18, 19).”
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460 · cited 1×
“In mice, nanoparticles have delivered Cas9 mRNA and ribonu-cleoproteins via systemic or local injection (5 – 12).”
Cited by
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Self-citationThe promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Chemistry of Lipid Nanoparticles for RNA Delivery
Eygeris, Y., Gupta, M., Kim, J., & Sahay, G. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00544 · Cited by 873
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 626
An ionizable lipid toolbox for RNA delivery
Han, X., Zhang, H., Butowska, K., Swingle, K. L., Alameh, M.-G., Weissman, D., & Mitchell, M. J. (2021) · Nature Communications · doi:10.1038/s41467-021-27493-0 · Cited by 628
Lipid nanoparticles for nucleic acid delivery: Current perspectives
Samaridou, E., Heyes, J., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 583
Therapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
A framework for designing delivery systems
Poon, W., Kingston, B. R., Ouyang, B., Ngo, W., & Chan, W. C. W. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0759-5 · Cited by 524
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
Cullis, P. R., & Felgner, P. L. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00977-6 · Cited by 503
Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs
Lokugamage, M. P., Vanover, D., Beyersdorf, J., Hatit, M. Z. C., Rotolo, L., Echeverri, E. S., Peck, H. E., Ni, H., Yoon, J.-K., Kim, Y., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00786-x · Cited by 495
Self-citationDevelopment of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
Abbott, T. R., Dhamdhere, G., Liu, Y., Lin, X., Goudy, L., Zeng, L., Chemparathy, A., Chmura, S., Heaton, N. S., Debs, R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.020 · Cited by 498
The challenge and prospect of mRNA therapeutics landscape
Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417
Bhatia, S. N., Chen, X., Dobrovolskaia, M. A., & Lammers, T. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00496-9 · Cited by 406
Brief update on endocytosis of nanomedicines
Patel, S., Kim, J., Herrera, M., Mukherjee, A., Kabanov, A. V., & Sahay, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.08.004 · Cited by 400
Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 385
Liu, J., Chang, J., Jiang, Y., Meng, X., Sun, T., Mao, L., Xu, Q., & Wang, M. (2019) · Advanced Materials · doi:10.1002/adma.201902575 · Cited by 373
Polymeric Delivery of Therapeutic Nucleic Acids
Kumar, R., Santa Chalarca, C. F., Bockman, M. R., Bruggen, C. V., Grimme, C. J., Dalal, R. J., Hanson, M. G., Hexum, J. K., & Reineke, T. M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00997 · Cited by 365
Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery
Buck, J., Grossen, P., Cullis, P. R., Huwyler, J., & Witzigmann, D. (2019) · ACS Nano · doi:10.1021/acsnano.8b07858 · Cited by 312
The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy
Francia, V., Schiffelers, R. M., Cullis, P. R., & Witzigmann, D. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00366 · Cited by 299
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 260
Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
Emerging mRNA technologies: delivery strategies and biomedical applications
Xiao, Y., Tang, Z., Huang, X., Chen, W., Zhou, J., Liu, H., Liu, C., Kong, N., & Tao, W. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00617g · Cited by 255
Long-term storage of lipid-like nanoparticles for mRNA delivery
Zhao, P., Hou, X., Yan, J., Du, S., Xue, Y., Li, W., Xiang, G., & Dong, Y. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.03.001 · Cited by 233
Core–shell nanostructures: perspectives towards drug delivery applications
Kumar, R., Mondal, K., Panda, P. K., Kaushik, A., Abolhassani, R., Ahuja, R., Rubahn, H.-G., & Mishra, Y. K. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01559h · Cited by 227
Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening
Guimaraes, P. P. G., Zhang, R., Spektor, R., Tan, M., Chung, A., Billingsley, M. M., El-Mayta, R., Riley, R. S., Wang, L., Wilson, J. M., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.028 · Cited by 220
Paunovska, K., Da Silva Sanchez, A. J., Sago, C. D., Gan, Z., Lokugamage, M. P., Islam, F. Z., Kalathoor, S., Krupczak, B. R., & Dahlman, J. E. (2019) · Advanced Materials · doi:10.1002/adma.201807748 · Cited by 205
Self-citationPiperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo
Ni, H., Hatit, M. Z. C., Zhao, K., Loughrey, D., Lokugamage, M. P., Peck, H. E., Cid, A. D., Muralidharan, A., Kim, Y., Santangelo, P. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32281-5 · Cited by 192
Self-citationRecent Advances in Lipid Nanoparticles for Delivery of mRNA
Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F., Zhang, Z., Li, Y., & Huang, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122682 · Cited by 173
Drug delivery systems for CRISPR-based genome editors
Madigan, V., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 172
Self-citationLoughrey, D., & Dahlman, J. E. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00601 · Cited by 173
Self-citationRui, Y., Wilson, D. R., Tzeng, S. Y., Yamagata, H. M., Sudhakar, D., Conge, M., Berlinicke, C. A., Zack, D. J., Tuesca, A., & Green, J. J. (2022) · Science Advances · doi:10.1126/sciadv.abk2855 · Cited by 166
Chen, J., Xu, Y., Zhou, M., Xu, S., Varley, A. J., Golubovic, A., Lu, R. X. Z., Wang, K. C., Yeganeh, M., Vosoughi, D., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2309472120 · Cited by 160
Liu, M., Wang, Y., Zhang, Y.-B., Hu, D., Tang, L., Zhou, B., & Yang, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02112-8 · Cited by 208
Species-dependent in vivo mRNA delivery and cellular responses to nanoparticles
Hatit, M. Z. C., Lokugamage, M. P., Dobrowolski, C. N., Paunovska, K., Ni, H., Zhao, K., Vanover, D., Beyersdorf, J., Peck, H. E., Loughrey, D., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-021-01030-y · Cited by 145
Self-citationLipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid
Jia, Y., Wang, X., Li, L., Li, F., Zhang, J., & Liang, X. (2023) · Advanced Materials · doi:10.1002/adma.202305300 · Cited by 171
Lee, S. M., Cheng, Q., Yu, X., Liu, S., Johnson, L. T., & Siegwart, D. J. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202013927 · Cited by 139
Wei, T., Cheng, Q., Farbiak, L., Anderson, D. G., Langer, R., & Siegwart, D. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c04707 · Cited by 135
Rhym, L. H., Manan, R. S., Koller, A. A., Stephanie, G., & Anderson, D. G. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01030-4 · Cited by 145
Physiological Barriers and Strategies of Lipid‐Based Nanoparticles for Nucleic Acid Drug Delivery
Hu, M., Li, X., You, Z., Cai, R., & Chen, C. (2023) · Advanced Materials · doi:10.1002/adma.202303266 · Cited by 167
Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies
Wei, P.-S., Thota, N., John, G., Chang, E., Lee, S., Wang, Y., Ma, Z., Tsai, Y.-H., & Mei, K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.030 · Cited by 149
Tanaka, H., Takahashi, T., Konishi, M., Takata, N., Gomi, M., Shirane, D., Miyama, R., Hagiwara, S., Yamasaki, Y., Sakurai, Y., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910575 · Cited by 126
Clinical delivery of circular RNA: Lessons learned from RNA drug development
Young, T. L., Wang, K. C., Varley, A., & Li, B. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114826 · Cited by 133
Mild Innate Immune Activation Overrides Efficient Nanoparticle‐Mediated RNA Delivery
Lokugamage, M. P., Gan, Z., Zurla, C., Levin, J., Islam, F. Z., Kalathoor, S., Sato, M., Sago, C. D., Santangelo, P. J., & Dahlman, J. E. (2020) · Advanced Materials · doi:10.1002/adma.201904905 · Cited by 126
Self-citationLi, G., Chen, T., Dahlman, J. E., Eniola‐Adefeso, L., Ghiran, I. C., Kurre, P., Lam, W. A., Lang, J. K., Marbán, E., Martín, P., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12305 · Cited by 129
Self-citationNakamura, T., Sato, Y., Yamada, Y., Abd Elwakil, M. M., Kimura, S., Younis, M. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114417 · Cited by 121
From structural design to delivery: mRNA therapeutics for cancer immunotherapy
Zhou, F., Huang, L., Li, S., Yang, W., Chen, F., Cai, Z., Liu, X., Xu, W., Lehto, V., Lächelt, U., et al. (2023) · Exploration · doi:10.1002/exp.20210146 · Cited by 128
Non-immunotherapy application of LNP-mRNA: Maximizing efficacy and safety
Vlatkovic, I. (2021) · Biomedicines · doi:10.3390/biomedicines9050530 · Cited by 112
The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery
Kularatne, R. N., Crist, R. M., & Stern, S. T. (2022) · Pharmaceuticals · doi:10.3390/ph15070897 · Cited by 109
Recent advances in nanoparticulate RNA delivery systems
Witten, J. J., Hu, Y., Langer, R., & Anderson, D. G. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307798120 · Cited by 121
Dobrowolski, C. N., Paunovska, K., Echeverri, E. S., Loughrey, D., Sanchez, A. J. D. S., Ni, H., Hatit, M. Z. C., Lokugamage, M. P., Kuzminich, Y., Peck, H. E., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01146-9 · Cited by 117
Self-citationSurface-Functionalized PEGylated Nanoparticles Deliver Messenger RNA to Pulmonary Immune Cells
Ke, X., Shelton, L., Hu, Y., Zhu, Y., Chow, E., Tang, H., Santos, J. L., & Mao, H. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c08268 · Cited by 105
Wan, F., Draz, M. S., Gu, M., Yu, W., Ruan, Z., & Luo, Q. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030352 · Cited by 109
Lipid Nanoparticles for Delivery of Therapeutic RNA Oligonucleotides
Moss, K. H., Popova, P. G., Hadrup, S. R., Astakhova, K., & Taskova, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01290 · Cited by 105
Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery
Melamed, J. R., Hajj, K. A., Chaudhary, N., Strelkova, D., Arral, M. L., Pardi, N., Alameh, M., Miller, J. B., Farbiak, L., Siegwart, D. J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.022 · Cited by 102
Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this?
O’Driscoll, C. M., Bernkop‐Schnürch, A., Friedl, J. D., Préat, V., & Jannin, V. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.03.027 · Cited by 99
Engineering nanoparticle toolkits for mRNA delivery
Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 98
Frameworks for transformational breakthroughs in RNA-based medicines
Androsavich, J. R. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00943-2 · Cited by 108
Designing lipid nanoparticles using a transformer-based neural network
Chan, A., Kirtane, A. R., Qu, Q. R., Huang, X., Woo, J., Subramanian, D. A., Dey, R., Semalty, R., Bernstock, J. D., Ahmed, T., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01975-4 · Cited by 118
de Carvalho, B. G., Ceccato, B. T., Michelon, M., Han, S. W., & de la Torre, L. G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010141 · Cited by 103
Applying artificial intelligence and computational modeling to nanomedicine
Hamilton, S., & Kingston, B. R. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103043 · Cited by 97
siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases
Kalita, T., Dezfouli, S. A., Pandey, L. M., & Uludağ, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112520 · Cited by 96
Liang, G., Cao, W., Tang, D., Zhang, H., Yu, Y., Ding, J., Karges, J., & Xiao, H. (2024) · ACS Nano · doi:10.1021/acsnano.3c11154 · Cited by 89
Petersen, D. M. S., Chaudhary, N., Arral, M. L., Weiss, R. M., & Whitehead, K. A. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.10.006 · Cited by 92
RNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82
Optimizing synthetic nucleic acid and protein nanocarriers: The chemical evolution approach
Freitag, F., & Wagner, E. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.03.005 · Cited by 92
TGFβ signaling pathways in human health and disease
Chen, P., Qin, L., & Simons, M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1113061 · Cited by 99
A comprehensive comparison of DNA and RNA vaccines
Wang, C., & Yuan, F. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115340 · Cited by 103
Detect and destroy: CRISPR-based technologies for the response against viruses
Freije, C. A., & Sabeti, P. C. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.003 · Cited by 83
Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery
Patel, S. K., Billingsley, M. M., Mukalel, A. J., Thatte, A. S., Hamilton, A. G., Gong, N., El-Mayta, R. D., Safford, H. C., Merolle, M. I., & Mitchell, M. J. (2023) · Theranostics · doi:10.7150/thno.89913 · Cited by 83
Cationic cholesterol-dependent LNP delivery to lung stem cells, the liver, and heart
Radmand, A., Kim, H., Beyersdorf, J. P., Dobrowolski, C. N., Zenhausern, R., Paunovska, K., Huayamares, S. G., Hua, X., Han, K., Loughrey, D., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307801120 · Cited by 88
Self-citationLipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics
Semple, S. C., Leone, R. D., Barbosa, C., Tam, Y. K., & Lin, P. J. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020398 · Cited by 90
Gan, Z., Lokugamage, M. P., Hatit, M. Z. C., Loughrey, D., Paunovska, K., Sato, M., Cristian, A., & Dahlman, J. E. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10161 · Cited by 77
Self-citationBecker, L. M., Chen, S.-H., Rodor, J., de Rooij, L. P. M. H., Baker, A. H., & Carmeliet, P. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac018 · Cited by 85
Sahel, D. K., Vora, L. K., Saraswat, A. L., Sharma, S., Monpara, J. D., D’souza, A. A., Mishra, D., Tryphena, K. P., Kawakita, S., Khan, S. U., et al. (2023) · Advanced Science · doi:10.1002/advs.202207512 · Cited by 88
Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies
Huang, X., Ma, Y., Ma, G., & Xia, Y. (2024) · Research · doi:10.34133/research.0370 · Cited by 96
Paunovska, K., Sanchez, A. J. D. S., Lokugamage, M. P., Loughrey, D., Echeverri, E. S., Cristian, A., Hatit, M. Z. C., Santangelo, P. J., Zhao, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c03741 · Cited by 80
Self-citationtRNA therapeutics for genetic diseases
Coller, J., & Ignatova, Z. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00829-9 · Cited by 76
Recent advances in polymeric materials for the delivery of RNA therapeutics
Ulkoski, D., Bak, A., Wilson, J. T., & Krishnamurthy, V. R. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1663822 · Cited by 73
Sago, C. D., Lokugamage, M. P., Loughrey, D., Lindsay, K. E., Hincapie, R., Krupczak, B. R., Kalathoor, S., Sato, M., Echeverri, E. S., Fitzgerald, J. P., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00847-9 · Cited by 76
Self-citationRaguram, A., An, M., Chen, P., & Liu, D. R. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02467-x · Cited by 90
The Transcriptional Response to Lung-Targeting Lipid Nanoparticles in Vivo
Radmand, A., Lokugamage, M. P., Kim, H., Dobrowolski, C. N., Zenhausern, R., Loughrey, D., Huayamares, S. G., Hatit, M. Z. C., Ni, H., Cid, A. D., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04479 · Cited by 79
Self-citationRegulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics
Vervaeke, P., Borgos, S. E., Sanders, N. N., & Combes, F. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114236 · Cited by 70
Natanzi, A. S., Poudineh, M., Karimi, E., Khaledi, A., & Kashani, H. H. (2025) · BMC Medicine · doi:10.1186/s12916-025-04323-4 · Cited by 88
Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application
Mashima, R., & Takada, S. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100341 · Cited by 78
Targeted nanomedicine: Lessons learned and future directions
Veiga, N., Diesendruck, Y., & Peer, D. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.010 · Cited by 73
Using Large Datasets to Understand Nanotechnology
Paunovska, K., Loughrey, D., Sago, C. D., Langer, R., & Dahlman, J. E. (2019) · Advanced Materials · doi:10.1002/adma.201902798 · Cited by 72
Self-citationNanoparticles-mediated CRISPR/Cas9 delivery: Recent advances in cancer treatment
Aghamiri, S., Talaei, S., Ghavidel, A. A., Zandsalimi, F., Masoumi, S., Hafshejani, N. H., & Jajarmi, V. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101533 · Cited by 81
Treating Cystic Fibrosis with mRNA and CRISPR
Sanchez, A. D. S., Paunovska, K., Cristian, A., & Dahlman, J. E. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.137 · Cited by 80
Self-citationHarnessing lipid nanoparticles for efficient CRISPR delivery
Yan, J., Kang, D. D., & Dong, Y. (2021) · Biomaterials Science · doi:10.1039/d1bm00537e · Cited by 72
Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Alkhaleefah, F. K., Rahmani, A. H., & Khan, A. A. (2022) · 癌症:英文版 · doi:10.1002/cac2.12366 · Cited by 77
Li, Z., Wang, J., Xu, J.-P., Wang, J., & Yang, X. F. (2023) · Military Medical Research · doi:10.1186/s40779-023-00447-x · Cited by 93
Structure and Morphology of Lipid Nanoparticles for Nucleic Acid Drug Delivery: A Review
Udepurkar, A. P., Devos, C., Sagmeister, P., Destro, F., Inguva, P., Ahmadi, S., Boulais, É., Quan, Y., Braatz, R. D., & Myerson, A. S. (2025) · ACS Nano · doi:10.1021/acsnano.4c18274 · Cited by 77
Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids
Khalil, I. A., Younis, M. A., Kimura, S., & Harashima, H. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00743 · Cited by 70
Recent advances in biomaterial-boosted adoptive cell therapy
Xue, Y., Che, J., Ji, X., Li, Y., Xie, J., & Chen, X. S. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00786f · Cited by 73
Therapeutic RNA Delivery for COVID and Other Diseases
Dobrowolski, C., Paunovska, K., Hatit, M. Z. C., Lokugamage, M. P., & Dahlman, J. E. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002022 · Cited by 63
Self-citationDelivery of mRNA for regulating functions of immune cells
Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 65
Makkar, S. K. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1675209 · Cited by 80
CRISPR nuclease off-target activity and mitigation strategies
Wienert, B., & Cromer, M. K. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.1050507 · Cited by 77
Metadata
- Authors
- Sago, C. D., Lokugamage, M. P., Paunovska, K., Vanover, D. A., Monaco, C. M., Shah, N. N., Gamboa Castro, M., Anderson, S. E., Rudoltz, T. G., Lando, G. N., Munnilal Tiwari, P., Kirschman, J. L., Willett, N., Jang, Y. C., Santangelo, P. J., Bryksin, A. V., & Dahlman, J. E.
- Affiliations
- Georgia Institute of Technology (US)
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA 30332;
- Corresponding author
- Dahlman, James E.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-10
- Volume
- 115
- Issue
- 42
- Pages
- E9944-E9952
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6196543
- OpenAlex
- W2893976143
- Cited by
- 313
- References
- 45
- Citations by year
- 2026: 37 · 2025: 45 · 2024: 46 · 2023: 44 · 2022: 58 · 2021: 31 · 2020: 36 · 2019: 16
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-11-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- HHS | National Institutes of Health (T32EB021962, T32GM008433, 5T32EB006343)
- Cystic Fibrosis Foundation (DAHLMA15XX0)
- Parkinson's Disease Foundation (PDF-JFA-1860)
- Bayer (AGE DTD)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- lipid nanoparticles, mRNA delivery, endothelial cells, CRISPR/Cas9 genome editing, siRNA delivery, single guide RNA, hepatocytes
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Animals, Cells, Cultured, Humans, Lipids, Mice, Inbred C57BL, RNA, Messenger, Gene Transfer Techniques, Hepatocytes, Endothelial Cells, Mice, Nanoparticles, High-Throughput Screening Assays, HEK293 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.